Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 8/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972266 | 0.94 | HCRTR1 (0.36) | CDK4CCND1HTR1AHCRTR1HCRTR2 | |
| SCHEMBL1973137 | 0.92 | HCRTR1 (0.38) | CDK4CCND1HTR1ASLC6A4HCRTR1 | |
| SCHEMBL1970279 | 0.90 | HCRTR2 (0.36) | CDK4CCND1HCRTR1HCRTR2ICMT | |
| SCHEMBL2404517 | 0.84 | HTR1A (0.42) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL1972371 | 0.84 | CDK4 (0.41) | CDK4CCND1HTR1ASLC6A4HCRTR1 | |
| SCHEMBL2406278 | 0.82 | HCRTR2 (0.41) | CDK4CCND1HTR1ASLC6A4HCRTR2 | |
| SCHEMBL1969631 | 0.82 | HTR1A (0.37) | CDK4CCND1HTR1ASLC6A4MPO | |
| SCHEMBL2407035 | 0.81 | HTR1A (0.44) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2407412 | 0.81 | HTR1A (0.42) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2409978 | 0.81 | HTR1A (0.44) | CDK4CCND1HTR1ASLC6A4HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CDK4 3031/4885CCND1 3178/4885HTR1A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.